Search Results

SAB Biotherapeutics today announced its new name, SAB BIO, and visual identity to more closely align with its mission to treat and prevent immune and autoimmune disorders with the use of its unique immunotherapy platform.

SAB Biotherapeutics, Inc. today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142.

SAB Biotherapeutics, announced that the U.S. Food and Drug Administration has provided clearance for the Company’s investigational new drug application to proceed for its phase 1 clinical trial for type 1 diabetes therapy SAB-142.

SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”) today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at the INNODIA Annual Meeting in Leuven, Belgium on April 11, 2024.

SAB Biotherapeutics today announced that effective June 4, its Chief Financial Officer Michael King will be departing the company to accept a role as CEO at a privately-held oncology company.

SAB Biotherapeutics announced that Jay Skyler, MD, MACP, FRCP has been appointed to the company’s Board of Directors.

SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present a poster at the ADA 84th Scientific Sessions on June 21-24, 2024 in Orlando, Florida.